Skip to main content

Peer Review reports

From: Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study

Original Submission
3 Dec 2010 Submitted Original manuscript
22 Dec 2010 Reviewed Reviewer Report - Peter Taylor
2 Jan 2011 Reviewed Reviewer Report - Andrew Östör
15 Feb 2011 Author responded Author comments - Ralph Preiss
Resubmission - Version 2
15 Feb 2011 Submitted Manuscript version 2
31 Mar 2011 Author responded Author comments - Ralph Preiss
Resubmission - Version 3
31 Mar 2011 Submitted Manuscript version 3
18 May 2011 Author responded Author comments - Ralph Preiss
Resubmission - Version 4
18 May 2011 Submitted Manuscript version 4
31 May 2011 Reviewed Reviewer Report - Andrew Östör
11 Jun 2011 Reviewed Reviewer Report - Peter Taylor
27 Jun 2011 Author responded Author comments - Ralph Preiss
Resubmission - Version 5
27 Jun 2011 Submitted Manuscript version 5
28 Jun 2011 Author responded Author comments - Ralph Preiss
Resubmission - Version 6
28 Jun 2011 Submitted Manuscript version 6
5 Jul 2011 Author responded Author comments - Ralph Preiss
Resubmission - Version 7
5 Jul 2011 Submitted Manuscript version 7
Publishing
7 Jul 2011 Editorially accepted
7 Jul 2011 Article published 10.1186/1471-2474-12-153

You can find further information about peer review here.

Back to article page